A groundbreaking topical gene therapy for 'butterfly skin disease' has transformed rare disease treatment. Suma Krishnan's ...

CEO Krish Krishnan highlighted Krystal Biotech's strong position across commercial, clinical, and financial areas. He noted the successful global expansion of VYJUVEK, particularly with the upcoming ...

(Reuters) -The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in ...

A Krystal Biotech researcher runs downstream filtration to purify the gene therapy product. A South Side biotech company is working to treat rare skin diseases by delivering gene therapy with a ...

Thank you for standing by and welcome to the Krystal Biotech Third Quarter 2023 Earnings Conference Call. As a reminder today’s conference call is being recorded. I would now like to hand the ...

In his 21 plus years of professional experience, Krishnan has been solving complex solution architecture problems around data warehousing and business intelligence for Fortune 1000 clients across the ...

Drug developer Suma Krishnan was 51 when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder, called dystrophic epidermolysis bullosa, in which the skin becomes as ...